Novartis Ag (NYSE: NVS)

Novartis Ag Return vs. S&P

Novartis Ag Company Info

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Valuation

Podcast Episodes

3 Biotech Companies Analyzed

We examine three biotech companies' past performances and future outlooks.

Shannon Jones  |  Feb 7, 2020

What Happened With CAR-T Stocks in 2018

Here’s how CAR-T therapies did in their first full year on the market.

Motley Fool Staff  |  Dec 18, 2018

Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.

Todd Campbell  |  Sep 5, 2017

Washington Cuts a Check to Spark Healthcare Innovation

The 21st Century Cures Act ignites innovation with perks to biopharma and medical device makers. Also, Kite Pharma and Novartis prep plans to pitch their CAR-T cancer therapies to the FDA.

Todd Campbell and Kristine Harjes  |  Dec 14, 2016